MULti-Tumour based prediction and manipulation of Immune Response

Project Information

MULTIR

Grant agreement ID: 101136926

DOI

10.3030/101136926

EC signature date 7 December 2023

Start date 1 January 2024

End date 31 December 2027

Funded under

• Health

Total cost

€ 8 547 711,50

EU contribution

€ 8 547 711,50

Coordinated by

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Documents, reports (3)

Policy brief formulating recommendations based on the research and innovation strand of the “Understanding (tumour-host interactions)”annual cluster meeting
Dissemination plan

Dissemination plan defined (updated M24)

Stakeholder engagement plan

Multi-stakeholder engagement plan defined

Websites, patent fillings, videos etc. (2)

Common video and brochure for the “Understanding (tumour-host interactions)” cluster

A common video and a brochure for the “ Understanding (tumour-host interactions)” cluster will be produced in collaboration with the other projects of the cluster

Launch of the website

Website open to the public

Publications

Conference proceedings (3)

Abstract 2190: Genomic scarring score is associated with T cell exhaustion in early stage non small cell lung cancer

Author(s): Ioannis Pateras, Konstantinos Ntostoglou, Georgios Christodoulopoulos, Katerina Tsilingiri, Anna Chalari, Giannis Vatsellas, Georgia Christopoulou, Pantelis Constantoulakis, Eleni Patsea, Konstantinos Potaris, Ioannis Vamvakaris, Dora Chatzidaki, Georgina Zachou, Athanasios Kotsakis, Apostolos Klinakis, Vassilis Georgoulias
Published in: Cancer Research, Issue 85, 2025, ISSN 0008-5472
Publisher: American Association for Cancer Research (AACR)
DOI: 10.1158/1538-7445.AM2025-2190

1233P Genomic scarring score as a criterion for PARP inhibitor administration in early-stage NSCLC

Author(s): A. Klinakis, K. Tsilingiri, A. Chalari, A. Voutsina, G. Christopoulou, G. Vatselas, K. Potaris, I. Vamvakaris, D. Hatzidaki, G. Zachou, V. Georgoulias, P. Konstantoulakis, A. Kotsakis
Published in: Annals of Oncology, Issue 35, 2024, ISSN 0923-7534
Publisher: Elsevier BV
DOI: 10.1016/J.ANNONC.2024.08.1292

Abstract 2919: Homologous recombination deficiency in non-small cell lung cancer: genetic and epigenetic causes beyond HRR

Author(s): Katerina Tsilingiri, Anna Chalari, Georgia Christopoulou, Alexandra Voutsina, Pantelis Constantoulakis, Konstantinos Potaris, Ioannis Vamvakaris, Dora Hatzidaki, Georgina Zachou, Giannis Vatsellas, Vassilis Georgoulias, Athanasios Kotsakis, Apostolos Klinakis
Published in: Cancer Research, Issue 85, 2025, ISSN 0008-5472
Publisher: American Association for Cancer Research (AACR)
DOI: 10.1158/1538-7445.AM2025-2919

Peer reviewed articles (4)

Cell-specific models reveal conformation-specific RAF inhibitor combinations that synergistically inhibit ERK signaling in pancreatic cancer cells

Author(s): Thomas Sevrin, Hiroaki Imoto, Sarah Robertson, Nora Rauch, Uscinnia Dyn’ko, Katerina Koubova, Kieran Wynne, Walter Kolch, Oleksii S. Rukhlenko, Boris N. Kholodenko
Published in: Cell Reports, Issue 43, 2024, ISSN 2211-1247
Publisher: Elsevier BV
DOI: 10.1016/J.CELREP.2024.114710

Genomic scarring score predicts the response to PARP inhibitors in non-small cell lung cancer

Author(s): Katerina Tsilingiri, Anna Chalari, Georgia Christopoulou, Alexandra Voutsina, Pantelis Constantoulakis, Κonstantinos Potaris, Ioannis Vamvakaris, Dora Hatzidaki, Georgina Zachou, Giannis Vatsellas, Vassilis Georgoulias, Athanasios Kotsakis, Apostolos Klinakis
Published in: npj Precision Oncology, Issue 8, 2024, ISSN 2397-768X
Publisher: Springer Science and Business Media LLC
DOI: 10.1038/S41698-024-00777-6

Cell State Transition Models Stratify Breast Cancer Cell Phenotypes and Reveal New Therapeutic Targets

Author(s): Oleksii S. Rukhlenko, Hiroaki Imoto, Ayush Tambde, Amy McGillycuddy, Philipp Junk, Anna Tuliakova, Walter Kolch, Boris N. Kholodenko
Published in: Cancers, Issue 16, 2025, ISSN 2072-6694
Publisher: MDPI AG
DOI: 10.3390/CANCERS16132354

cSTAR analysis identifies endothelial cell cycle as a key regulator of flow-dependent artery remodeling

Author(s): Hanqiang Deng, Oleksii S. Rukhlenko, Divyesh Joshi, Xiaoyue Hu, Philipp Junk, Anna Tuliakova, Boris N. Kholodenko, Martin A. Schwartz
Published in: Science Advances, Issue 11, 2025, ISSN 2375-2548
Publisher: American Association for the Advancement of Science (AAAS)
DOI: 10.1126/SCIADV.ADO9970